Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories
about
Chaperones in hepatitis C virus infectionHepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagyCyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a ReinfectionMembrane dynamics associated with viral infectionInfection Counter: Automated Quantification of in Vitro Virus Replication by Fluorescence MicroscopyCharacterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compoundThe Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.Hepatitis C virus and autophagy.Entangled in a membranous web: ER and lipid droplet reorganization during hepatitis C virus infection.Current trends in the treatment of hepatitis C: interventions to avoid adverse effects and increase effectiveness of anti-HCV drugs.Lipid droplet functions beyond energy storage.Characterization of the anti-hepatitis C virus activity of new non-peptidic small-molecule cyclophilin inhibitors with a potential for broad anti-Flaviviridae activity.HCV NS5A dimer interface residues regulate HCV replication by controlling its self-interaction, hyperphosphorylation, subcellular localization and interaction with cyclophilin A
P2860
Q26771251-E317E550-D667-4491-9469-9DE85ED100CFQ26801207-1B10C466-B591-48C2-9723-BF6B579DD3E5Q27468931-F9198FDC-3653-49C9-807E-17B4B7CD2889Q28069980-FAF7A869-9F5C-4CFA-8D3D-8E74DAD326DFQ28364857-F6465A01-5DA5-4161-A1D0-CFADA5FA9851Q28551538-1EE8FE35-B340-4138-9E56-882B3C3C2FE4Q33918841-C8FCA0F7-CA6A-4948-A66C-C7EA5C104767Q35742761-46399946-5D9C-4179-BF6B-6A82402B32F6Q35774186-76319EF2-C485-428F-BD38-AB9D6ECF9EFDQ36652533-FB9BB664-01D2-46C8-875E-2060BDA4D2B9Q38848095-A119BDF4-6A65-478A-9F8D-1F4F7E013C20Q39092871-933B14E0-8C31-42FF-97E2-3E78AE9A3949Q39452331-5870C6B9-133A-4C7D-8708-18DD441D3E1EQ54212189-74A50E11-B7A0-4482-9805-1EF0CF23F32CQ56396163-90633C2C-DCBD-41B7-BC3E-196EFC1D2365
P2860
Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Cyclophilin and NS5A inhibitor ...... mbrane-vesicle viral factories
@ast
Cyclophilin and NS5A inhibitor ...... mbrane-vesicle viral factories
@en
type
label
Cyclophilin and NS5A inhibitor ...... mbrane-vesicle viral factories
@ast
Cyclophilin and NS5A inhibitor ...... mbrane-vesicle viral factories
@en
prefLabel
Cyclophilin and NS5A inhibitor ...... mbrane-vesicle viral factories
@ast
Cyclophilin and NS5A inhibitor ...... mbrane-vesicle viral factories
@en
P2093
P2860
P356
P1476
Cyclophilin and NS5A inhibitor ...... mbrane-vesicle viral factories
@en
P2093
Malcolm Wood
Michael Bobardt
Philippe A Gallay
Udayan Chatterji
P2860
P304
P356
10.1128/AAC.04958-14
P407
P50
P577
2015-02-09T00:00:00Z